| Miller, Christopher J |
AMEND, NCT05887271: A Randomised, Controlled Trial of a Low-energy Diet for Improving Functional Status in Heart Failure With PRESERVED Ejection Fraction Preserved Ejection Fraction |
|
|
| Recruiting | 2/3 | 102 | Europe | Low calorie meal replacement plan, Diet, Cardiovascular magnetic resonance (CMR) imaging and magnetic resonance spectroscopy, CMR, Transthoracic echocardiography, Blood test, Electrocardiogram, ECG, Accelerometery, 6 minute walk test (6MWT), Skeletal muscle strength using handgrip strength and quadriceps (Cybex dynamometer), Assessment of quality of life and heart failure symptoms, Assessment of sarcopenia, Assessment of frailty, Qualitative interview, Skeletal muscle magnetic resonance spectroscopy | University of Leicester, University of Oxford, University of Manchester | Heart Failure With Preserved Ejection Fraction, Heart Failure, Diastolic, Diabetes Mellitus, Type 2, Diabetes Mellitus Type 2 in Obese, Obesity Adult Onset | 06/25 | 01/26 | | |
NCT04312230: The Role of Biomarkers in Inherited Cardiac Conditions |
|
|
| Withdrawn | N/A | 750 | Europe | | Manchester University NHS Foundation Trust | Inherited Cardiac Conditions | 11/21 | 11/21 | | |
BHIP-CCM, NCT05997836: Behavioral Health Interdisciplinary Program - Collaborative Chronic Care Model () Enhancement Project 2.0 |
|
|
| Active, not recruiting | N/A | 81424 | US | Implementation Facilitation, IF, Centralized Technical Assistance, CTA | VA Office of Research and Development, US Department of Veterans Affairs Office of Mental Health and Suicide Prevention | Mental Health | 10/24 | 10/25 | | |
NCT06388512: iMRI Prone Positioning Frame Design Feasibility Study |
|
|
| Not yet recruiting | N/A | 5 | US | prototype prone positioning device | University of Kansas Medical Center, Continuum Educational Technologies | Epilepsy, Pulmonary Embolism | 09/25 | 09/25 | | |
| Active, not recruiting | N/A | 10000 | Europe | | Manchester University NHS Foundation Trust, University of Pittsburgh Medical Center | Cardiovascular Diseases | 12/29 | 12/29 | | |
| Whorwell, Peter |
| Completed | N/A | 153 | Europe | Galacto-oligosaccharides (GOS), Prebiotic, Maltodextrine, Placebo | Clasado, CR2O B.V. | Irritable Bowel Syndrome, Irritable Bowel Syndrome - Constipation, Irritable Bowel Syndrome - Diarrhoea, Irritable Bowel Syndrome - Mixed | 08/24 | 08/24 | | |
| Bundred, Nigel |
| Active, not recruiting | 3 | 257 | Europe | trastuzumab, lapatinib ditosylate, laboratory biomarker analysis, adjuvant therapy, neoadjuvant therapy, therapeutic conventional surgery | Institute of Cancer Research, United Kingdom, University of Manchester, Manchester University NHS Foundation Trust, Cancer Research UK, Novartis | Breast Cancer | 08/17 | 09/25 | | |
|
| Recruiting | N/A | 600 | Europe | Syantra DX Breast Cancer | Syantra Inc. | Breast Cancer Female | 12/21 | 12/22 | | |
| McGrath, Brendan A |
| Recruiting | N/A | 80 | Europe | Prototype medical device (SEA CtV) | Manchester University NHS Foundation Trust, Manchester Metropolitan University | Tracheostomy | 12/24 | 12/24 | | |
| Taylor, Paul |
| Recruiting | N/A | 148 | Europe | Proton beam therapy | University College, London, Asthma + Lung UK, Mesothelioma UK, University of Sheffield | Malignant Pleural Mesothelioma | 03/29 | 09/29 | | |
| Singh, Dave |
TRECOS, NCT06264674: Comparison Between CHF5993 pMDI 200/6/12.5 µg HFA-152a VS CHF5993 pMDI 200/6/12.5 µg HFA-134a in Subjects With Asthma (). |
|
|
| Active, not recruiting | 3 | 837 | Europe, RoW | CHF5993 200/6/12.5 μg pMDI HFA-152a, HFA-152a propellant, Inhaler CHF5993 200/6/12.5 μg pMDI HFA-134a, HFA-134a propellant | Chiesi Farmaceutici S.p.A. | Asthma | 07/25 | 09/25 | | |
| Completed | 2 | 337 | Europe, Canada, US, RoW | Tezepelumab, Placebo | AstraZeneca, Amgen | Chronic Obstructive Pulmonary Disease (COPD) | 11/23 | 01/24 | | |
|
NCT06166056: A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Inhaled CHF6333 After Single Doses in Healthy Volunteers and After Single and Repeated Doses in Subjects With Bronchiectasis |
|
|
| Recruiting | 1/2 | 45 | Europe | CHF6333, CHF6333 Placebo | Chiesi Farmaceutici S.p.A. | Bronchiectasis | 06/25 | 06/25 | | |
NCT04769869: A Clinical Trial in Healthy Volunteers and Patients With Mild Asthma to Investigate a New Medicine (AZD4604) for the Treatment of Asthma |
|
|
| Completed | 1 | 110 | Europe | AZD4604 for inhalation via DPI, Placebo for AZD4604 for inhalation via DPI, AZD4604 for IV administration, AZD4604 for oral administration | AstraZeneca | Asthma | 01/23 | 01/23 | | |
| Completed | 1 | 117 | Europe | KN-002 | Kinaset Therapeutics Inc | Asthma COPD | 12/23 | 07/24 | | |
NCT05195008: A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics, With Target Occupancy Study of BIIB113 in Healthy Participants |
|
|
| Completed | 1 | 72 | Europe | BIIB113, BIIB113-Matching Placebo, 11^C]BIO-1819578 | Biogen | Healthy Volunteer | 07/23 | 07/23 | | |
| Recruiting | 1 | 120 | Europe | SPYVAC01 | SpyBiotech Limited | Cytomegalovirus Infections | 04/25 | 04/25 | | |
NCT06154837: A Study for GSK3862995B in Healthy Participants and Participants With Chronic Obstructive Pulmonary Disease |
|
|
| Recruiting | 1 | 130 | Europe | GSK3862995B, Placebo | GlaxoSmithKline | Pulmonary Disease, Chronic Obstructive | 04/26 | 04/26 | | |
| Terminated | 1 | 78 | Europe, RoW | ARO-MUC5AC, Placebo | Arrowhead Pharmaceuticals, Arrowhead Pharmaceuticals, Inc. | Asthma, Chronic Obstructive Pulmonary Disease | 11/24 | 11/24 | | |
NCT05965089: A First in Human Study of AX-202 in Healthy Subjects and Patients With Psoriasis. |
|
|
| Completed | 1 | 58 | Europe | Placebo, AX-202 | Arxx Therapeutics | Healthy Volunteers, Mild to Moderate Psoriasis | 07/24 | 07/24 | | |
NCT06433921: A Study to Compare the Relative Potency of Salbutamol Administered Via Metered Dose Inhalers (MDI) Containing Propellants HFA-152a to HFA-134a in Mild Asthmatics Aged 18 to 65 Inclusive |
|
|
| Recruiting | 1 | 91 | Europe | Salbutamol HFA-152a, Salbutamol HFA-134a, Placebo | GlaxoSmithKline | Asthma, Mild Asthma | 03/25 | 03/25 | | |
| Schmitt, Matthias |
| Active, not recruiting | 2 | 154 | Europe | Trientine, Cufence, Placebo | Manchester University NHS Foundation Trust, National Institute for Health Research, United Kingdom, University of Manchester, University of Liverpool, Univar BV, University of Oxford | Hypertrophic Cardiomyopathy | 04/24 | 10/24 | | |
| Active, not recruiting | N/A | 10000 | Europe | | Manchester University NHS Foundation Trust, University of Pittsburgh Medical Center | Cardiovascular Diseases | 12/29 | 12/29 | | |
| Fox, David |
| Active, not recruiting | 2 | 104 | NA | Placebo for VIB4920, VIB4920 with TNFi, VIB4920 without TNFi | National Institute of Allergy and Infectious Diseases (NIAID), Immune Tolerance Network (ITN) | Rheumatoid Arthritis | 08/25 | 03/26 | | |
| Completed | 1/2 | 17 | US | Brentuximab Vedotin, Adcetris®, Placebo, Placebo for brentuximab vedotin | National Institute of Allergy and Infectious Diseases (NIAID), Immune Tolerance Network (ITN), Seagen Inc., PPD, Rho Federal Systems Division, Inc. | Diffuse Cutaneous Systemic Sclerosis, Scleroderma, dcSSc | 04/23 | 04/23 | | |
| Wang, Ran |
NCT04133714: A Multi-center RCT Study on the Efficacy and Mechanism of Multi-channel tDCS in Rehabilitation of Cognitive Function After Stroke |
|
|
| Recruiting | N/A | 180 | RoW | multi-channel tDCS, single-channel tDCS | Second Affiliated Hospital, School of Medicine, Zhejiang University | Cognitive Dysfunction | 03/23 | 12/23 | | |
